A Lawrie1, G Penney, A Templeton. 1. Department of Obstetrics and Gynaecology, Aberdeen Maternity Hospital, UK.
Abstract
OBJECTIVE: To assess the effectiveness and acceptability of oral misoprostol, self-administered 12 h before surgery, as a cervical priming agent prior to day case suction termination of pregnancy. DESIGN: Randomised trial comparing oral misoprostol with the local standard regimen of vaginal misoprostol. SUBJECTS:Sixty consecutive women scheduled for day case suction termination in one gynaecology unit. INTERVENTIONS: Cervical priming with misoprostol 400 mg orally, 12 h prior to surgery or 800 mg vaginally, two to four hours prior to surgery. MAIN OUTCOME MEASURES: Basal cervical dilatation, cumulative force required to dilate the cervix to 9 mm, operative blood loss and side effects (nausea, vomiting, diarrhoea, abdominal pain and vaginal bleeding). RESULTS: There were no significant differences between the oral and vaginal treatment groups in relation to basal dilatation, cumulative force to achieve 9 mm dilatation or gastrointestinal side effects. However, those in the oral group experienced more severe pain and heavier pre-operative bleeding. Two patients in the oral group experienced incomplete abortion at home after taking misoprostol and a further patient required early admission because of heavy bleeding. CONCLUSIONS: Because of the unpredictability of action of oral misoprostol, with incomplete abortion or heavy bleeding occurring prior to admission in three patients, we cannot recommend the dosage schedule evaluated here for routine clinical use.
RCT Entities:
OBJECTIVE: To assess the effectiveness and acceptability of oral misoprostol, self-administered 12 h before surgery, as a cervical priming agent prior to day case suction termination of pregnancy. DESIGN: Randomised trial comparing oral misoprostol with the local standard regimen of vaginal misoprostol. SUBJECTS: Sixty consecutive women scheduled for day case suction termination in one gynaecology unit. INTERVENTIONS: Cervical priming with misoprostol 400 mg orally, 12 h prior to surgery or 800 mg vaginally, two to four hours prior to surgery. MAIN OUTCOME MEASURES: Basal cervical dilatation, cumulative force required to dilate the cervix to 9 mm, operative blood loss and side effects (nausea, vomiting, diarrhoea, abdominal pain and vaginal bleeding). RESULTS: There were no significant differences between the oral and vaginal treatment groups in relation to basal dilatation, cumulative force to achieve 9 mm dilatation or gastrointestinal side effects. However, those in the oral group experienced more severe pain and heavier pre-operative bleeding. Two patients in the oral group experienced incomplete abortion at home after taking misoprostol and a further patient required early admission because of heavy bleeding. CONCLUSIONS: Because of the unpredictability of action of oral misoprostol, with incomplete abortion or heavy bleeding occurring prior to admission in three patients, we cannot recommend the dosage schedule evaluated here for routine clinical use.
Authors: Shagufta Parveen; Zaffar Abbas Khateeb; S M Mufti; M A Shah; Vishal R Tandon; S Hakak; Z Singh; Shagufta Yasmeen; Shakeel A Mir; Rehana Tabasum; Nasreen Jan Journal: Indian J Pharmacol Date: 2011-04 Impact factor: 1.200